Leukemia Research
Volume 24, Issue 7 , Pages 597-600 , July 2000

Refractory anemia with ringed sideroblasts with a low IPSS score progressed rapidly with de novo appearance of multiple karyotypic abnormalities and into acute erythroleukemia (AML-M6A)

Received 29 September 1999 ,Accepted 5 February 2000.

References 

  1. Bennett JM, Catovsky D, Daniel MT, et al.  Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 1982;5l:189–199
  2. Coiffier B, Adeleine P, Viala JJ, et al.  Dysmyelopoietic syndromes: a search for prognostic factors in 193 patients. Cancer. 1983;52:83–90
  3. Juneja SK, Imbert M, Jouault H, Scoazec JY, Sigaux F, Sultan C. Haematological features of primary myelodysplastic syndromes (PMDS) at initial presentation: a study of 118 cases. J. Clin. Pathol. 1983;36:129–135
  4. Mufti GJ, Stevens JR, Oscier DG, Hamblin TJ, Machin D. Myelodysplastic syndromes: a scoring system with prognostic significance. Br. J. Haematol. 1985;59:425–433
  5. Varela BL, Chuang C, Woll JE, Bennett JM. Modifications in the classification of primary myelodysplastic syndromes: the addition of a scoring system. Hematological. Oncol. 1985;3:55–63
  6. Foucar K, Langdon RM, Armitage JO, Olson DB, Carroll TJ. Myelodysplastic syndromes: a clinical and pathologic analysis of 109 cases. Cancer. 1985;56:553–561
  7. Tricot G, Vlietinck R, Boogaerts MA, et al.  Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis. Br. J. Haematol. 1985;60:19–32
  8. Sanz GF, Sanz MA, Vallespi T, et al.  Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood. 1989;74:395–408
  9. Greenberg P, Cox C, LeBeau MM, et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088
  10. Garand R, Duchayne E, Blanchard D, et al.  Minimally differentiated erythroleukaemia (AML M6 ‘variant’): a rare subset of AML distinct from AML M6. Br. J. Haematol. 1995;90:868–875
  11. Oguma S, Yoshida Y, Uchino H, Maekawa T. Factors influencing nonleukemic death in refractory anemia, refractory anemia with ring sideroblasts, and refractory anemia with excess of blasts. Cancer Res. 1987;47:3559–3602
  12. Toyama K, Ohyashiki K, Yoshida Y, et al.  Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. Leukemia. 1993;7:499–508
  13. Nakamura H. Cytogenetic heterogeneity in erythroleukemia defined as M6 by the French–American–British (FAB) Cooperative Group criteria. Leukemia. 1989;3:305–309

PII: S0145-2126(00)00029-1

Leukemia Research
Volume 24, Issue 7 , Pages 597-600 , July 2000

Article Tools

* Image Usage & Resolution